Lilly's Q3 Earnings Estimate Falls to $6.67 on Acquired R&D Charges

The third-quarter 2026 earnings estimate for Eli Lilly fell from $9.87 to $6.67 per share, according to Yahoo Finance, because of acquired in-process R&D charges. These one-time accounting entries, booked when a drug company buys early-stage assets, cut reported profit while revenue is still expected to grow. Lilly reports October 29.